ReviewJournal of the Endocrine Society2026
Growth hormone retesting for idiopathic isolated growth hormone deficiency during and after puberty: a systematic review.
Review in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Growth hormone retesting for idiopathic isolated growth hormone deficiency during and after puberty: a systematic review.Journal of the Endocrine Society · 2026Review
- Preferences for (Dis)Continuing Growth Hormone Treatment at Mid-Puberty in Patients with Transient Idiopathic Isolated Growth Hormone Deficiency: A Qualitative Analysis.Hormone research in paediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Idiopathic isolated growth hormone deficiency (IIGHD) is difficult to diagnose due to the day-to-day variation in growth hormone (GH) secretion and limitations of GH stimulation testing (GHST). Although recombinant human GH (rhGH) is typically continued until near adult height (NAH), many patients no longer show deficiency at that point. The optimal timing and method for retesting GH secretion remain unclear. Objective: To summarize the currently available GHSTs in children with IIGHD, with particular focus on diagnostic strategies in the peripubertal period, timing of retesting, and the role of sex steroid priming. Methods: A systematic literature search was conducted in 4 databases up to June 2025. Studies were included if they reported on GH retesting in children with IIGHD. Data were extracted on patient characteristics, GHST protocols, priming strategies, cutoff values, and reversal rates. Risk of bias was assessed using the ROBINS-I tool. Results: Thirty-one studies involving 2057 patients were included. Retesting occurred after 1-2 years of rhGH treatment, during mid-puberty, or at (N)AH, with mean reversal rates of 46.4%, 46.3%, and 69.6%, respectively. Priming with sex steroids was inconsistently applied, using testosterone in boys and ethinyl estradiol in girls. A GH peak cutoff of 7 μg/L was most commonly used, though values varied. Mid-pubertal retesting may reduce false-positive diagnoses and treatment burden. Conclusion: Retesting strategies for IIGHD should be individualized based on treatment response and pubertal development. Early retesting is advised for poor responders, while mid-puberty retesting suits most patients with normal development. Priming is recommended in older prepubertal children. Standardization of GHST protocols and long-term outcome studies are needed to optimize care and reduce overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.